Hold ABT at $103.50 with 10-15% Q3 trim and $97.50 stop; technical deterioration and Q3 catalyst risk preclude directional conviction
Hold ABT at $103.50 with a 10-15% trim into Q3 2026 earnings, a hard closing stop at $97.50, no new long initiation, and re-engagement only on two-of-four confirmations (close above 200 SMA with volume >25M, MACD higher low, RSI bullish divergence, or forward EPS stabilization post-Q3). This posture captures the structural floor's defensive value (2.46% yield, 1.7x dividend coverage, 0.4x net debt/EBITDA) while honoring technical deterioration's warning that conviction-sized directional positioning is chronically late in this name; the pattern evidence across seven prior September 2026 decisions shows Hold producing the highest alpha (+0.5% to +0.8%) versus Underweight (-0.6% to -1.2%) and Overweight (-1.3% on 9/16).
| Position | Action |
|---|---|
| Heading into Q3 2026 earnings (mid-October) | Trim 10-15% of position to modestly reduce concentration risk while preserving upside if Q3 delivers a beat-and-raise |
| Confirmed close above 200 SMA ($104.11) on volume >25M shares | Re-engage with incremental long position |
| Capitulation flush to $93-95 with MACD/RSI confirmation | Re-engage with incremental long position on bounce signal |
| Position size if any re-engagement triggers met | Two-of-four confirmations required: close above 200 SMA with volume, MACD higher low, RSI bullish divergence, or forward EPS stabilization post-Q3 |
ABT is a value-with-catalyst story at an inflection point — the legal overhang is cleared, valuation is historically cheap for a Dividend King with fortress financials, and the macro backdrop (higher-for-longer rates, soft landing) is tailor-made for defensive healthcare compounders with growing dividends.
| Indicator | Value | Signal |
|---|---|---|
| close | $102.98 | neutral |
| 50 SMA | $106.17 | bearish |
| 200 SMA | $104.11 | bearish |
| 10 EMA | $103.85 | bearish |
| RSI (14) | 39.43 | bearish |
| MACD line | -1.62 | bearish |
| MACD signal | -0.79 | bearish |
| MACD histogram | -0.83 | bearish |
| Bollinger Middle | $107.46 | bearish |
| Bollinger Upper | $117.41 | neutral |
| Bollinger Lower | $97.51 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Flush to $93-95 with MACD/RSI confirmation
Then: Initiate or add to long position modestly
Forward P/E of 17.0x is cheap for a quality healthcare compounder with mid-teens ROIC.
↩ rebuts: “Bear uses trailing P/E of 33x, which is a trap — distorted by one-time tax benefit”
EV: Target: $115-$120 over 6 months (implied +12-17% from ~$103); 2-3:1 reward/risk skew to upside over 6-12 months · concedes: Bear's technical read is not wrong — ABT is below moving averages, MACD is negative, distribution is real; Bear's technical arguments are transitory — they reflect August profit-taking cooling off, not deteriorating fundamentals; The settlement is a 'modest EPS drag' numerically — the bull case is about removal of uncertainty, not magnitude of the charge
Abbott's "discount" multiple is a market signal of structural headwinds, not a value opportunity — forward EPS estimates are aggressive, legal overhang is carved up not resolved, technicals show distribution, and competitive risks from GLP-1s and Dexcom threaten Libre growth, making Q3 a likely downward revision event rather than a catalyst.
· concedes: ABT has a strong balance sheet; Dividend King pedigree is real; Legal headline has been cleared; Diversification is a relative strength versus ISRG; Higher-for-longer rates do help dividend payers relative to bonds; Real rates helping ABT relative to bonds
→ vs conservative: Technical pattern-matching (price below MAs, MACD -0.83, RSI under 40) is misread as bearish when it actually represents classic reversal setup at major support—August rally from 87 to 116 happened on exactly this kind of oversold configuration
→ vs conservative: The $385M infant formula settlement is being framed as a new negative when it is actually the overhang clearing; DOJ chose civil over criminal path, Abbott admitted nothing, no operational consequences—this is a known, finite, resolved event institutions are accumulating into, not fleeing from
→ vs conservative: Macro fears about crypto rotation limiting defensive flows are misread; zero Fed cuts in 2026 means elevated real yields and greater need for income-generating assets like ABT's 2.46% dividend yield
→ vs neutral: Holding at 103 with intent to trim 25-40% into Q3 earnings is the opposite of how wealth is built—you're selling into an asymmetric catalyst with positive expected value that could be a major re-rating event
→ vs neutral: The neutral 'Hold' thesis that acknowledges value exists but plans to trim contradicts itself; if you believe the value is there at 103, you should be adding, not preparing to reduce
| bullish |
| VWMA(20) | $104.77 | bearish |
| ATR | $2.43 | neutral |
Support: 102.98 · 101.95 · 100 · 97.51 · 93.25 · 83.72 | Resistance: 104.11 · 107.46 · 108 · 110 · 112 · 113 · 116.67
ABT trades below all key moving averages in a confirmed primary downtrend; the August rally to $116.67 has been fully retraced. The 200 SMA at $104.11 sits just above price as critical resistance while the lower Bollinger band at $97.51 is the key support to watch—VWMA confirms distribution with the volume-weighted average above spot price. RSI at 39.43 and MACD histogram at -0.83 indicate bearish momentum is accelerating but not yet at deeply oversold extremes. The rating is HOLD—existing longs should reduce exposure while fresh entries await a confirmed reversal or test of the $97.51 level with bullish momentum evidence.
Market Cap
$178.2 B
Stock Price
~$103.0
52-Week Range
$81.97 – $137.49
50-Day Avg
$106.02
200-Day Avg
$105.20
P/E (TTM)
33.3x
Forward P/E
17.0x
PEG Ratio
1.88
P/B
3.49
EV / Revenue (TTM)
~4.1x
Dividend Yield
2.46%
Beta
0.586
EPS (TTM)
$3.09
Forward EPS
$6.07
Revenue 2021 ($M)
43,653
Revenue 2022 ($M)
40,109
Revenue 2023 ($M)
41,950
Revenue 2024 ($M)
44,328
Revenue TTM
$46.6B
YoY Growth 2022
–8.1%
YoY Growth 2023
+4.6%
YoY Growth 2024
+5.7%
Gross Profit 2021 ($M)
24,511
Gross Profit 2022 ($M)
22,134
Gross Profit 2023 ($M)
23,244
Gross Profit 2024 ($M)
25,009
Gross Margin 2021
56.1%
Gross Margin 2022
55.2%
Gross Margin 2023
55.4%
Gross Margin 2024
56.4%
Gross Margin (TTM)
~56.9%
Operating Income 2021 ($M)
8,362
Operating Income 2022 ($M)
6,478
Operating Income 2023 ($M)
6,825
Operating Income 2024 ($M)
8,053
Operating Margin 2021
19.2%
Operating Margin 2022
16.1%
Operating Margin 2023
16.3%
Operating Margin 2024
18.2%
Operating Margin (TTM)
~14.7%
Operating Margin Normalized
~18%
Net Income 2021 ($M)
6,933
Net Income 2022 ($M)
5,723
Net Income 2023 ($M)
13,402
Net Income 2024 ($M)
6,524
Diluted EPS 2021
$3.91
Diluted EPS 2022
$3.26
Diluted EPS 2023
$7.64
Diluted EPS 2024
$3.72
Normalized 2024 EPS
~$3.00–$3.20
R&D 2021 ($M)
2,888
R&D 2022 ($M)
2,741
R&D 2023 ($M)
2,844
R&D 2024 ($M)
2,942
SG&A 2021 ($M)
11,248
SG&A 2022 ($M)
10,949
SG&A 2023 ($M)
11,697
SG&A 2024 ($M)
12,332
Total Assets 2022 ($M)
74,438
Total Assets 2023 ($M)
73,214
Total Assets 2024 ($M)
81,414
Total Assets 2025 ($M)
86,713
Total Equity 2022 ($M)
36,686
Total Equity 2023 ($M)
38,603
Total Equity 2024 ($M)
47,664
Total Equity 2025 ($M)
52,130
Total Debt 2022 ($M)
17,716
Total Debt 2023 ($M)
15,628
Total Debt 2024 ($M)
15,021
Total Debt 2025 ($M)
13,860
Long-Term Debt 2022 ($M)
14,522
Long-Term Debt 2023 ($M)
13,599
Long-Term Debt 2024 ($M)
12,625
Long-Term Debt 2025 ($M)
9,896
Cash & Equivalents 2022 ($M)
9,882
Cash & Equivalents 2023 ($M)
6,896
Cash & Equivalents 2024 ($M)
7,616
Cash & Equivalents 2025 ($M)
8,522
Net Debt 2022 ($M)
6,891
Net Debt 2023 ($M)
7,783
Net Debt 2024 ($M)
6,509
Net Debt 2025 ($M)
4,407
Inventory 2022 ($M)
6,173
Inventory 2023 ($M)
6,570
Inventory 2024 ($M)
6,194
Inventory 2025 ($M)
6,488
Receivables 2022 ($M)
6,218
Receivables 2023 ($M)
6,565
Receivables 2024 ($M)
6,925
Receivables 2025 ($M)
7,929
Goodwill & Intangibles 2022 ($M)
33,253
Goodwill & Intangibles 2023 ($M)
32,494
Goodwill & Intangibles 2024 ($M)
29,755
Goodwill & Intangibles 2025 ($M)
29,561
Current Ratio 2022
1.63
Current Ratio 2023
1.64
Current Ratio 2024
1.67
Current Ratio 2025
1.58
Debt/Equity
~27%
Operating Cash Flow 2022 ($M)
9,581
Operating Cash Flow 2023 ($M)
7,261
Operating Cash Flow 2024 ($M)
8,558
Operating Cash Flow 2025 ($M)
9,566
CapEx 2022 ($M)
(1,777)
CapEx 2023 ($M)
(2,202)
CapEx 2024 ($M)
(2,207)
CapEx 2025 ($M)
(2,171)
Free Cash Flow 2022 ($M)
7,804
Free Cash Flow 2023 ($M)
5,059
Free Cash Flow 2024 ($M)
6,351
Free Cash Flow 2025 ($M)
7,395
FCF Yield
~4.1%
Dividends Paid 2022 ($M)
(3,309)
Dividends Paid 2023 ($M)
(3,556)
Dividends Paid 2024 ($M)
(3,836)
Dividends Paid 2025 ($M)
(4,116)
Buybacks 2022 ($M)
(3,795)
Buybacks 2023 ($M)
(1,227)
Buybacks 2024 ($M)
(1,295)
Buybacks 2025 ($M)
(893)
Net Debt Repayment 2022 ($M)
(699)
Net Debt Repayment 2023 ($M)
(2,475)
Net Debt Repayment 2024 ($M)
(537)
Net Debt Repayment 2025 ($M)
(1,614)
Dividend Payout Ratio (Dividend/FCF)
~56%
Profit Margin (TTM)
~11.6%
Profit Margin Normalized
~16%
EBITDA Margin (TTM)
~25.1%
ROE
10.6%
ROA
5.3%
ROIC (adjusted)
mid-teens
Net Debt/EBITDA
~0.4x
% Off 52-Week High
~25%
Tangible Book Value ($B)
$22.6B
Strengths
Concerns
ABT is a mega-cap ($178.2B) defensive healthcare compounder trading ~25% below its 52-week high at a forward P/E of 17.0x with a 4.1% FCF yield. The company generates strong free cash flow ($7.4B in 2025) supporting a sustainable 56% dividend payout ratio and over 50 years of consecutive dividend growth. Note that 2024 reported EPS of $7.64 was materially distorted by an $8B non-cash tax benefit — normalized EPS is approximately $3.00-$3.20, with operating income and cash flow being more reliable indicators of true earnings power.
Macro: Fed policy: Polymarket 96% probability of zero 2026 rate cuts (+2.1pp WoW). Inflation: Polymarket 18% odds >4.5% in 2026, 8% odds >5%. Recession odds: US 6% (-3.0pp WoW), UK 4%, Japan 4%. Risk appetite rotated into crypto/digital assets rather than traditional equities or defensives.